107 related articles for article (PubMed ID: 9390037)
1. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer.
Müller W; Schneiders A; Heider KH; Meier S; Hommel G; Gabbert HE
J Pathol; 1997 Oct; 183(2):222-7. PubMed ID: 9390037
[TBL] [Abstract][Full Text] [Related]
2. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer.
Müller W; Noguchi T; Wirtz HC; Hommel G; Gabbert HE
J Pathol; 1999 Oct; 189(2):186-93. PubMed ID: 10547573
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva.
Tempfer C; Gitsch G; Haeusler G; Reinthaller A; Koelbl H; Kainz C
Cancer; 1996 Jul; 78(2):273-7. PubMed ID: 8674003
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer.
Müller W; Grabsch H; Takeno S; Noguchi T; Hommel G; Gabbert HE
Anticancer Res; 2000; 20(3A):1787-92. PubMed ID: 10928108
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases.
Schröder W; Rudlowski C; Biesterfeld S; Knobloch C; Hauptmann S; Rath W
Anticancer Res; 1999; 19(5B):3901-6. PubMed ID: 10628329
[TBL] [Abstract][Full Text] [Related]
8. Preferential overexpression of CD44v5 in advanced gastric carcinoma Goseki grades I and III.
Stachura J; Krzeszowiak A; Popiela T; Urbańczyk K; Pituch-Noworolska A; Wieckiewicz J; Zembala M
Pol J Pathol; 1999; 50(3):155-61. PubMed ID: 10624117
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M
J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348
[TBL] [Abstract][Full Text] [Related]
11. Splice variants of CD44 in human cervical cancer stage IB to IIB.
Kainz C; Kohlberger P; Sliutz G; Tempfer C; Heinzl H; Reinthaller A; Breitenecker G; Koelbl H
Gynecol Oncol; 1995 Jun; 57(3):383-7. PubMed ID: 7539775
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of bcl-2 expression in gastric cancer.
Müller W; Schneiders A; Hommel G; Gabbert HE
Anticancer Res; 1998; 18(6B):4699-704. PubMed ID: 9891543
[TBL] [Abstract][Full Text] [Related]
13. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
Nguyen VN; Mirejovský T; Melinová L; Mandys V
Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa.
Menges M; Goebel R; Pueschel W; Zeitz M; Stallmach A
Exp Mol Pathol; 2002 Jun; 72(3):207-12. PubMed ID: 12009784
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse.
Beham-Schmid C; Heider KH; Hoefler G; Zatloukal K
J Pathol; 1998 Dec; 186(4):383-9. PubMed ID: 10209487
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
17. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
Regauer S; Ott A; Berghold A; Beham A
J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD44 molecule in renal cell carcinoma.
Lucin K; Matusan K; Dordević G; Stipić D
Croat Med J; 2004 Dec; 45(6):703-8. PubMed ID: 15578803
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia.
Polkowski WP; Skomra DG; Mielko J; Wallner GT; Szumiło J; Zinkiewicz K; Korobowicz EM; van Lanschot JJ
Eur J Surg Oncol; 2004 Dec; 30(10):1084-92. PubMed ID: 15522555
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer.
Huang CS; Shen CY; Wang HW; Wu PE; Cheng CW
Clin Chim Acta; 2007 Sep; 384(1-2):69-74. PubMed ID: 17651715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
